Biopeople

Senior executive

Senior executive

21.08.2014 - Swedish pharmaceutical company Medivir has a new president and CEO: board member Niklas Prager is succeeding Maris Hartmanis effective September 1st.

Prager has long experience of senior executive positions in trade and industry - both as CEO and as board member. He is currently chairman of the board of Qbtech AB and a member of the board of Egain Group AB. Before that, he was chairman of the boards of Biophausia AB, Envirotainer AB and Michael Berglund Search Group AB. He has also served as the CEO of Pfizer AB, Envirotainer AB and Qbtech AB. Stockholm-based Medivir expects a strong contribution to the company's strategic business development and commercialisation of its product portfolio. Prager commented: "An update of Medivir’s strategic plan is the number one priority, and work on this is already well under way."

http://www.european-biotechnology-news.com/people/bio-people/2014/niklas-prager.html

01.07.2014 Tumour angiogenesis pioneer Napoleone Ferrara has been appointed Chairman of Tiziana Life Sciences plc’s (London) Scientific Advisory Board.

Tiziana, SL

Honoured with the 2010 Lasker Award for his discovery of the angiogenesis drug target VEGF, the Distinguished Professor of Pathology at the University of California’s School of Medicine in San Diego will advise Tiziana on its  BCL3 targeted cancer drugs, which are in development for mestastasis prevention. 

26.06.2014 Ophthalmic gene therapy company GenSight Biologics SA (Paris) has named Jean-Philippe Combal as its Chief Operating Officer to push development of its Phase I LHON replacement therapy (GS010).

GenSight, SL

Combal worked with Fovea Pharmaceuticals from 2006 to 2011, where he initially led product development before moving on to become VP Strategic Marketing of Fovea-Sanofi’s Ophthalmic Division. Since 2011, he has developed Galderma International’s marketing of clinical projects. In his more than 20 years in the industry, Combal has worked at Servier, Pierre-Fabre Medicament, Fournier-Solvay Pharma and ExonHit Therapeutics.

24.06.2014 Rolf Stahel joined Ergomed’s (Guildford, UK) board as Non-Executive Chairman.

Ergomed, SL

Stahel brings over 30 years experience in the pharma industry to the drug development services company. He led Shire Pharmaceuticals Group plc as CEO from 1994-2003 and worked before that for 27 years with Wellcome plc. Stahel has also played the Non-Executive Chairman role at Newron Pharmaceuticals, Cosmo Pharmaceuticals, PowderMed and EUSA Pharma.

19.06.2014 Recombinant spider silk producer AMSilk GmbH (Planegg, Germany) has named Jens Klein as its Managing Director.

AmSilk

He succeeds Axel Leimer, who had led the company since 2008. Klein previously worked with industrial biotech company Evonik Industries AG and was a member of the executive board of med-tech, biotech, and high-tech investment company Mulligan BioCapital AG. Prior to Mulligan, he was the commercial head and managing director of subsidiaries of Fresenius AG (Bad Homburg).

17.06.2014 Udit Batra has taken the helm as new CEO and President at Merck Millipore’s Consumer Health Division from Robert Yates, who has left the company.

Lichtbildatelier Eva Speith

Prior to his new position, Batra served as Head of Consumer Health at the German company. The chemical engineer joined Merck Serono from Novartis, where he had held a range of executive management positions since 2006. Before joining Novartis, Batra worked at Merck & Co., McKinsey and Johnson & Johnson.

29.05.2014 Drug discovery provider Sygnature Discovery Ltd. has appointed Gerry Thomas as its new Director of Business Development.

Sygnature

Thomas spent more than 20 years in drug discovery and development at Boots Pharmaceuticals, BASF/Knoll, OSI Pharmaceuticals, Prosidion and Shire Pharmaceuticals. At Sygnature, the medicinal chemist will be instrumental in promoting the company’s integrated drug discovery capabilities and expertise across Europe and North America. 

27.05.2014 Drug giant Sanofi S.A. (Paris) has filled the newly-created position of Chief Patient Officer with Anne C. Beal, a public health specialist with a focus on providing access to high-quality health care.

Sanofi S.A.

Beal’s responsibility will be to infuse the patient perspective in Sanofi’s activities, ranging from early-stage R&D through to market availability of novel healthcare solutions. A pediatrician by profession, Beal joins Sanofi from the Patient Centered Outcomes Research Institute (PCORI), the United States’ largest research institute focused on patient-centered outcomes research, where she was Deputy Executive Director and Chief Officer for Engagement. Prior to PCORI, Beal was president of the Aetna Foundation, the independent charitable and philanthropic arm of Aetna Inc. She holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University. 

22.05.2014 F. Hoffmann-La Roche has promoted Genentech’s former VP of clinical hematology and oncology Dietmar Berger to lead the pharma giant’s clinical development for oncology and hematology.

Roche

He succeeds Sandra Homing, who was named Chief Medical Officer last January. Berger brings the company more than 20 years of experience in the field. Before joining Roche, he co-led oncology research at Bayer HealthCare AG and at Amgen Inc.

20.05.2014 Alessandra Cervino has joined Paris-based metagenomics specialist Enterome Bioscience SA as Head of Discovery.

Michael Guez

The 38-old reseacher brings the firm over 15 years of experience in the discovery and development of genetic and genomic biomarkers. Before joining Enterome, Cervino was VP R&D and Biostatistics at TCLand Expression, Head of Statistical Sciences at Scripps Florida, and group leader in statistical genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co.

15.05.2014 ADC specialist Glythera (UK) has named Ian Evetts as its new Commercial Director.

Glythera

Evett brings in more than 20 years experience in the pharmaceutical industry with a track record of senior strategic and operational roles, among them Managing Director at Atebion BDS Ltd., Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.

Vorherige Seite2/20Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • MAGFORCE6.47 EUR19.8%
  • SANTHERA80.00 CHF15.1%
  • LONZA101.50 CHF9.7%

FLOP

  • WILEX2.26 EUR-31.1%
  • MOLOGEN7.30 EUR-22.8%
  • VITA 343.79 EUR-19.9%

TOP

  • SANTHERA80.00 CHF3802.4%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR186.9%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014


Current issue

All issues

Product of the week

Products